[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universitair Ziekenhuis Brussel\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":661},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,78,0,25,[9,42,67,95,127,153,176,203,227,249,282,305,324,343,365,387,411,432,458,484,506,538,571,597,632],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100473956","anatomy-based-fitting-in-unexperienced-cochlear-implant-users-100473956",false,"NCT05451628","Anatomy-Based Fitting in Unexperienced Cochlear Implant Users","ABFmulti","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Post-lingual onset of severe to profound sensory-neural hearing loss in the implanted ear(s)\n* Post-operative Computed Tomography (CT) scan of the CI electrode available\n* Pre-operative result of pure-tone audiometry, speech test in quiet and in noise available\n* Subject implanted with MED-EL cochlear implant(s)\n* Subjects received a Flex28, FlexSoft or Standard electrode\n* Subject planned to receive a SONNET 2, SONNET 3 or RONDO 3 audio processor on the newly implanted side\n* Audio processor not yet activated on the newly implanted side\n* The most apical active electrode contact has to be inserted at least 450°\n* Minimum of 10 active channels can be activated\n* Fluent in the language of the test centre\n* Signed and dated Informed Consent Form (ICF) before the start of any study-specific procedure\n\nExclusion Criteria:\n\n* Lack of compliance with any inclusion criteria\n* Electric Acoustic Stimulation (EAS) user (user of an EAS audio processor)\n* Implanted with C40+, C40X and C40C\n* Implanted with an Auditory Brainstem Implant (ABI) or Split electrode array\n* Anything that, in the opinion of the Investigator, would place the subject at increased risk or pre-clude the subject's full compliance with or completion of the study","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","Severe to profound hearing loss affects 0,8% of the global population. For these people, a conventional hearing aid often does not provide sufficient benefit. However, these people can benefit from a cochlear implant (CI). A CI needs to be individually programmed (fitted) for each recipient. A fitting \"map\" is defined as a set of electrical parameters that are individually adapted to a recipient's needs to achieve optimal sound perception. At present, most CI recipients are fitted with a default frequency allocation map that doesn't take individual variability in size and shape of the cochlea into account. In this study, a fitting strategy based on the post-operative CT scan, that will allow the audiologist to set a frequency-band distribution for CI fitting that may be more closely aligned to the natural tonotopic frequency distribution of a normal hearing cochlea, will be evaluated.",[27,28],"Cochlear Implants","Sensorineural Hearing Loss","RECRUITING","2026-06-29",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2022-03-30",{"date":37,"type":21},"2027-01",{"name":39,"class":40},"Universitair Ziekenhuis Brussel","OTHER",2,{"id":43,"slug":44,"hasResults":12,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":41},"100559534","multimodal-biopsychosocial-teleprehabilitation-for-total-knee-arthroplasty-100559534","NCT06565377","Multimodal Biopsychosocial Teleprehabilitation for Total Knee Arthroplasty","The Added Value of Multimodal Biopsychosocial Teleprehabilitation in People Undergoing Total Knee Arthroplasty: a Pilot\u002FFeasibility Trial","MULTIPREP","Inclusion Criteria:\n\n* People scheduled for elective primary TKA at one of the participating hospitals;\n* Being over 18 years old;\n* Dutch speaking\u002Freading\n\nExclusion Criteria:\n\n* Doing activities that make them feel out of breath for 300 minutes or more per week on average;\n* Orthopedic, neurological, cardiovascular or any other condition\u002Fcomorbidity that leads to an overall contraindication for moderate physical activity;\n* Cognitive impairment (≥11 on 6-item Cognitive Impairment Test and\u002For unable to understand the study instructions);\n* Presence of uncontrolled inflammatory arthritides (e.g., rheumatoid arthritis, gout);\n* Uncontrolled psychiatric disorders;\n* Active cancer and\u002For active cancer treatment ((hormonal) maintenance therapy is allowed);\n* People undergoing emergency (non-elective) TKA.",{"count":20,"type":21},[24],"Knee replacement surgeries are one of the most frequently performed elective surgeries, with approximately 29,000 such procedures carried out annually in Belgium. Although these surgeries have been increasingly refined over the years, leading to better surgical outcomes, there is still room for improvement in terms of pre-surgical biopsychosocial patient preparation. Such preparation aims to optimally inform patients before their surgery and to start preparing them for rehabilitation and resumption of activities after surgery. Therefore, we aim to assess the added value and feasibility of prehabilitation within the knee replacement care pathway.\n\nThe primary objective is to investigate the feasibility, acceptability and safety of multimodal biopsychosocial teleprehabilitation (BPS-teleprehab) for people undergoing total knee arthroplasty (TKA).\n\nThe secondary objective is to explore the effect of BPS-teleprehab versus best-evidence preoperative advice for people undergoing TKA on activity outcomes, functioning, pain, symptoms of central sensitization, quality of life, cognitive-emotional factors, joint awareness, satisfaction with the surgery, healthcare and medication use and productivity loss.\n\nThe tertiary objective is to explore baseline associations between the collected outcome measures, demographics and medical data in people scheduled for TKA.\n\nFurthermore, this pilot trial will inform potential protocol modifications in prepara- tion of an eventual fully powered randomized controlled trial to investigate the ef- fectiveness of BPS-teleprehab in people undergoing TKA.",[54],"Total Knee Arthroplasty",[56,57,58],"total knee arthroplasty","knee replacement","prehabilitation","2026-06-11",{"date":61,"type":33},"2026-06-15",{"date":63,"type":33},"2024-07-31",{"date":65,"type":21},"2027-08-31",{"name":39,"class":40},{"id":68,"slug":69,"hasResults":12,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":74,"sex":75,"minAge":18,"maxAge":76,"enrollmentInfo":77,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},"100642286","corpus-luteum-function-and-cardiovascular-adaptation-in-a-natural-mock-cycle-100642286","NCT07648381","Corpus Luteum Function and Cardiovascular Adaptation in a Natural MOCK Cycle.","CLEAR","Inclusion Criteria:\n\n* Age below 40 years\n* Regular menstrual cycles (between 25-35 days)\n* Normal BMI between 18.5 and 35\n\nExclusion Criteria:\n\n* Underlying renal or cardiac disease\n* Hypertension\n* Diabetes mellitus\n* Contraceptive use less than 3 months before MOCK cycle, including: IUD (hormonal and copper), hormonal patch, contraceptive pill (combination and mini), hormonal intravaginal ring, contraceptive implant, contraceptive injection.\n* Ovarian stimulation during the previous three months\n* History of recurrent pregnancy loss (defined as 2 or more previous pregnancy losses before 24 weeks gestation).",true,"FEMALE","40 Years",{"count":78,"type":21},118,"OBSERVATIONAL","In infertility treatment, embryos are created in vitro after eggs have been fertilised by sperm using in vitro fertilisation or intracytoplasmic sperm injection techniques. These embryos, resulting from hormonal ovarian stimulation, can be transferred shortly after egg retrieval (fresh transfer) or frozen for later use. Both natural menstrual cycles and artificial cycles (using hormones to mimic a normal cycle) can prepare the uterus for embryo transfer. Patients with regular menstrual cycles often prefer the non-medicated approach. However, these cycles offer less flexibility in timing because they rely on ovulation. As the number of FET cycles increases worldwide, scientists are exploring the possibility of inducing ovulation in smaller follicles to increase the flexibility of natural cycles. However, the safety for future pregnancies is unknown. This study aims to better understand the function of the corpus luteum, the follicle remnant in the ovary after ovulation, by measuring several factors that change throughout the cycle due to substances produced by the corpus luteum. The results of the study will have a direct impact on clinical practice by increasing the flexibility of frozen transfer cycles.",[82,83,84,85],"Menstrual Cycle","Luteal Phase Progesterone Levels","Luteal Phase Adaptation","MOCK Cycle","NOT_YET_RECRUITING","2026-06-09",{"date":61,"type":33},{"date":90,"type":21},"2026-07-01",{"date":92,"type":21},"2028-09",{"name":39,"class":40},1,{"id":96,"slug":97,"hasResults":12,"nctId":98,"briefTitle":99,"officialTitle":100,"acronym":101,"eligibilityCriteria":102,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":103,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":111,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":94},"100533757","frozen-shoulder-treatment-with-intra-articular-corticosteroid-injection-and-suprascapular-nerve-block-100533757","NCT06229964","Frozen Shoulder Treatment With Intra-Articular Corticosteroid Injection and Suprascapular Nerve Block","A Double Blinded Randomized Controlled Trial (RCT) Exploring the Additional Effect of a Suprascapular Nerve Block in Combination With an Intra-Articular Corticosteroid Injection in Patients With Frozen Shoulder","FROSTBLOCK","Inclusion Criteria:\n\n* Written informed consent to participate in the study must be obtained from the subject prior to initiation of any study-mandated procedure\n* Suffering from Frozen Shoulder, defined as: Frozen shoulder is a self-limiting disease characterized by pain and functional restriction in both active and passive shoulder motion lasting more than 1 month, for which radiographic findings of the shoulder joint are unremarkable.\n* Dutch or French speaking persons\n* Age ≥ 18 years\n\nExclusion Criteria:\n\n* Subjects with posttraumatic or postsurgical stiff shoulder syndrome\n* History of trauma at the onset of symptoms\n* Subjects with rheumatologic or neurologic disease involving the shoulder\n* Subjects with cervical radiculopathy\n* Coagulation disorder\n* Hypersensitivity to local anesthetics or MRI contrast agent\n* Inability to understand the study procedures\n* Psychiatric illness\n* Pregnancy\n* Subjects who have received prior SSNB in the homolateral shoulder\n* Subjects who have received an IACI in the homolateral shoulder in the 3 months before inclusion• Systematic yeast infections\n* Hypovolaemia\n* Infections at the injection site\n* Medical history of malignant hyperthermia, major conduction disorders, acute cardiac decompensation, shock conditions, convulsions\n\nControl subjects for the diagnostic accuracy part of the study protocol\n\n* Inclusion criteria:\n* Written informed consent to participate in the study must be obtained from the sub-ject prior to initiation of any study-mandated procedure\n* Subjects suffering from shoulder pain that do not fulfill the diagnostic criteria of Frozen Shoulder\n* Dutch or French speaking persons\n* Age ≥ 18 years\n* Contralateral shoulder of Frozen Shoulder subjects\n* Exclusion criteria\n* Subjects with posttraumatic or postsurgical stiff shoulder syndrome\n* History of trauma at the onset of symptoms\n* Subjects with rheumatologic or neurologic disease involving the shoulder\n* Subjects with cervical radiculopathy\n* Coagulation disorder or treatments with anticoagulants\n* Hypersensitivity to MRI contrast agent\n* Inability to understand the study procedures\n* Psychiatric illness\n* Pregnancy\n* Systematic yeast infections\n* Hypovolaemia\n* Infections at the injection site\n* Medical history of malignant hyperthermia, major conductin disorders, acute cardi-ac decompensation, shock conditions, convulsions","99 Years",{"count":105,"type":21},110,[24],"Frozen shoulder remains a challenging disease to treat as pain and loss of range of motion can persist for many months or even years. This loss of function can have a severe impact on the patient's activities, participation and overall quality of life.\n\nThe use of ultrasound-guided (USG) suprascapular nerve blocks (SSNB) and\u002For intra-articular corticoid injections (IACI) has been supported by many studies. However, double blinded randomized clinical trials using a combination of SSNB and IACI are rare.\n\nThe primary objective of this study is to compare the effectiveness of a glenohumeral IACI combined with a SSNB, compared to a glenohumeral IACI combined with a sham SSNB. Outcome measures of interest are shoulder-related disability reported by the patients, shoulder pain and shoulder stiffness. These outcome parameters will be compared between both treatment arms with an intention-to-treat analysis.\n\nAs key secondary objectives, the investigators aim to identify which physical examination tests, or combinations of those, are correlated with MRI diagnostic criteria and favor a more positive evolution. Finally, through predictive analysis the investigators will try to establish which patients benefit the most from the combined SSNB + IACI.",[109,110],"Frozen Shoulder","Adhesive Capsulitis",[109,112,113,114,115,116,117,118],"Adhesive Capsulitis of the Shoulder","Intra-articular corticosteroid injection","ultra-sound guided injection","suprascapular nerve block","Joint Diseases","Musculoskeletal Diseases","Bursitis","2026-05-28",{"date":121,"type":33},"2026-06-01",{"date":123,"type":33},"2025-02-28",{"date":125,"type":21},"2028-05-31",{"name":39,"class":40},{"id":128,"slug":129,"hasResults":12,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":133,"eligibilityCriteria":134,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":147,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":94},"100510961","phase-2-macrophage-imaging-using-ga-mmr-vhh2-in-lung-cancer-patients-100510961","NCT05933239","Macrophage Imaging Using Ga-MMR-VHH2 in Lung Cancer Patients","A Phase II Study to Evaluate the Imaging Potential of 68GaNOTA-Anti-MMR VHH2 for in Vivo Imaging of MMR-expressing Macrophages by Means of Positron Emission Tomography (PET) in Patients With Non-small Cell Lung Cancer (NSCLC)","MAGMA","Inclusion Criteria:\n\n* Patients who have given informed consent\n* Patients at least 18 years old\n* Patient with local, locally advanced or metastatic disease of non-small cell lung cancer, who is planned for resection or surgical biopsy of at least one lesion. In order to minimise partial volume effect, the diameter of the tumour to be resected or biopsied should be ≥ 10 mm in short axis for invaded adenopathies and ≥ 10 mm in long axis for all other types of lesions\n* Patients who participated already in this study can be included if the subject meets all of the inclusion and none of the exclusion criteria at time of second inclusion.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status 3 or higher\n* Pregnant patients\n* Breast feeding patients\n* Patients with any serious active infection\n* Patients who have any other life-threatening illness or organ system dysfunction, which in the opinion of the investigator would either compromise patient safety or interfere with the evaluation of the safety of the test radiopharmaceutical\n* Patients who are unlikely to cooperate with the requirements of the study\n* Patients who are unwilling and\u002For unable to give informed consent\n* Patients at increased risk of death from a pre-existing concurrent illness",{"count":136,"type":21},20,[138],"PHASE2","Phase II study to evaluate the clinical potential of 68GaNOTA-anti-MMR-VHH2 for in vivo imaging of Macrophage Mannose Receptor (MMR)-expressing Macrophages by means of Positron Emission Tomography (PET) in patients with non-small cell lung cancer (NSCLC) planned for surgical resection.",[141],"Non-small Cell Lung Cancer",[143,144,145,146],"PET\u002FCT","MMR-PET\u002FCT","Macrophage PET\u002FCT","CD206",{"date":121,"type":33},{"date":149,"type":33},"2023-03-30",{"date":151,"type":21},"2027-04-01",{"name":39,"class":40},{"id":154,"slug":155,"hasResults":12,"nctId":156,"briefTitle":157,"officialTitle":157,"acronym":158,"eligibilityCriteria":159,"healthyVolunteers":74,"sex":75,"minAge":4,"maxAge":4,"enrollmentInfo":160,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":162,"conditions":163,"keywords":166,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":94},"100465159","the-flora-project-in-search-for-the-microbial-cause-of-chronic-endometritis-and-the-most-appropriate-treatment-to-obtain-a-successful-pregnancy-ivficsi-100465159","NCT05337072","The FLORA-project: in Search for the Microbial Cause of Chronic Endometritis and the Most Appropriate Treatment to Obtain a Successful Pregnancy IVF\u002FICSI","FLORA","Inclusion Criteria:\n\n* Women planned for IVF\u002FICSI treatment at Brussels IVF (UZ Brussel)\n* Women who undergo a diagnostic hysteroscopy in preparation of their treatment\n\nExclusion criteria:\n\n* If an interventional instead of a diagnostic hysteroscopy in planned\n* In the occurence If a previous history of chronic endometritis and the use of antibiotics in the last 3 months.",{"count":161,"type":21},1000,"Chronic endometritis is an inflammatory condition of the endometrium. This inflammation can negatively affect fertility and pregnancy. The pathology is frequently (+-10%) observed in women with fertility problems. Today, diagnosis of chronic endometritis is not evident, since no well-validated classification scales are available. In the UZ Brussel the pathology department applies its own in-house scoring system, based on the presence and position of plasma cells within the histological images.\n\nDespite limited research so far, it recently became clear that the endometrium is colonized by micro-organisms (the microbiome). However, it is still unclear what role these microorganisms play in chronic endometritis and fertility problems. Chronic endometritis is often diagnosed in the context of fertility problems, and the patient is treated 'blindly' with broad-spectrum antibiotics such as doxycycline. Broad-spectrum antibiotics unnecessarily eradicate many microorganisms in our body, including the ones that positively influence implantation. The exact cause of chronic endometritis is unknown, so treatment remains empirical. The research and knowledge in the endometrial microbiome is constantly expanding, mainly due to the rise of research into the links between pathologies and human microbiota. It is becoming increasingly clear that the composition of the microbiome can play a vital role in health and disease. Regarding the influence of the endometrial microbiome on different pathologies, such as chronic endometritis and implantation failure or miscarriage, there is still no consensus. Despite multiple studies on the endometrial microbiome, we are not yet able to define a normal or healthy endometrial microbiome.\n\nIn this project, we want to gain insight into the microorganisms that are present in the female reproductive tract based on various techniques. The analyses will performed on a transvaginal ultrasound, endometrial biopsies which will be harvested during (guided biopsy) and after (blind pipelle biopsy) the hysteroscopy and a vaginal swab. The biopsy is routinely taken at Brussels IVF for the detection of plasma cells in the anatomopathology lab for the diagnosis of chronic endometritis. In the microbiology lab we will investigate which microorganisms are present in the female reproductive tract with and without the histological diagnosis of chronic endometritis. This will be done based on the state-of-the-art analytical techniques metagenomics (sequencing) and culturomics (culture).",[164,165],"Endometritis; Chronic","Subfertility",[167],"Microbiome","2026-05-12",{"date":170,"type":33},"2026-05-15",{"date":172,"type":33},"2023-07-01",{"date":174,"type":21},"2026-12-31",{"name":39,"class":40},{"id":177,"slug":178,"hasResults":12,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":182,"eligibilityCriteria":183,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":184,"enrollmentInfo":185,"targetDuration":4,"studyType":22,"phases":187,"briefSummary":188,"conditions":189,"keywords":191,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":202,"locationsCount":41},"100466565","cognitive-motor-telerehabilitation-in-ms-100466565","NCT05355389","Cognitive-motor Telerehabilitation in MS","Cognitive-motor Telerehabilitation in Multiple Sclerosis","CoMoTeMS","Inclusion Criteria:\n\n* Clinically definite multiple sclerosis (revised McDonald criteria 2017)\n* Expanded Disability Status Scale (EDSS) below 6.0\n* Digit span backwards z-score between \\[-3 and -0.5\\] standard deviations below the median of the normative values\n* Age between 18 and 65\n* Able to safely perform motor rehabilitation in the home situation (assessed by rehabilitation physician and\u002For occupational or physiotherapist)\n\nExclusion Criteria:\n\n* Cognitive rehabilitation within six months before inclusion\n* Inpatient multidisciplinary rehabilitation program within three months before inclusion or planned inpatient program during trial\n* Start of or switch in immunomodulator treatment within three months before inclusion\n* Less than one month post-exacerbation\n* Major psychiatric or medical disorder that could influence cognitive functions\n* Combined vision with optimal correction below 0.6 on Snellen Visual Acuity Test\n* Unable or unwilling to undergo EEG or MRI\n* Refusing informed consent","65 Years",{"count":186,"type":21},90,[24],"The primary goal of this project is providing evidence that a home-based combined cognitive-motor training program improves cognition in persons with multiple sclerosis (MS), compared to single cognitive and motor rehabilitation. Secondary goals are to assess the effects on walking performance and to identify the mechanisms of improvement and predictors of treatment response. The main backbone of this project will be a randomized controlled two-centre clinical trial, in which an at-home computerised cognitive-motor rehabilitation program using telemedicine aimed at improving working memory in persons with MS will be evaluated. Based on the information gathered during this trial, possible mechanisms of improvement will be identified by analysing anatomical and neurophysiological changes on structural MRI and resting-state and task-related EEG before and after rehabilitation. Furthermore, factors that can predict treatment response to the rehabilitation program will be identified.",[190],"Multiple Sclerosis",[192,193,194,195],"multiple sclerosis","cognitive rehabilitation","cognitive-motor rehabilitation","telerehabilitation","2026-05-04",{"date":198,"type":33},"2026-05-08",{"date":200,"type":33},"2022-09-01",{"date":65,"type":21},{"name":39,"class":40},{"id":204,"slug":205,"hasResults":12,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":216,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":94},"100617480","the-value-of-spleen-stiffness-measurement-in-patients-with-pbc-100617480","NCT07319169","The Value of Spleen Stiffness Measurement in Patients With PBC","Inclusion Criteria:\n\n* ≥18y\n* Out-patient, followed at the UZ Brussels\n* Diagnosis of PBC based on cholestasis, AMA positivity and\u002For biopsy.\n* Under treatment with ursodeoxycholic acid and\u002For bezafibrate\n\nExclusion Criteria:\n\n* \\\u003C18y\n* Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.",{"count":210,"type":21},125,[24],"Recent evidence suggests that combining liver stiffness measurement (LSM) with spleen stiffness measurement (SSM) significantly improves risk stratification in patients with PBC. In a study the addition of spleen stiffness to liver stiffness enhanced the prediction of liver decompensation, providing a more precise evaluation of portal hypertension. Furthermore, when combined with platelet count, this approach effectively identified patients with a low probability of harboring HRVs. This could allow clinicians to safely avoid unnecessary endoscopic procedures in selected patients, improving patient comfort and reducing healthcare costs. Therefore, our patients participating in this trial will undergo follow up (every 6 months) as per Standard of care. This includes a blood draw, FibroScan and Ultrasound. Together with this, 2 questionnaires will be completed (not as per SOC) and during the FibroScan, a spleen stiffness measurement will be performed.",[214,215],"Primary Biliary Cholangitis","Spleen Stiffness",[217,218],"spleen stiffness","primary biliairy cholangitis","2026-04-30",{"date":221,"type":33},"2026-05-01",{"date":223,"type":21},"2026-07",{"date":225,"type":21},"2028-01",{"name":39,"class":40},{"id":228,"slug":229,"hasResults":12,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":235,"briefSummary":236,"conditions":237,"keywords":240,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":94},"100620601","assessing-signatures-for-fibrosis-detection-in-chronic-liver-disease-a-step-beyond-conventional-biomarkers-100620601","NCT07359742","Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers","Assessing Signatures for Fibrosis Detection in Chronic Liver Disease: A Step Beyond Conventional Biomarkers.","Inclusion Criteria:\n\n* ≥18y\n* Chronic liver disease: alcohol, metabolic dysfunction associated steatotic liver disease, viral hepatitis, autoimmune hepatitis, cholestatic liver disease and hemochromatosis\n\nExclusion Criteria:\n\n* \\\u003C18y\n* Acute hepatitis\n* Contra-indication for transient elastography (Fibroscan®) such as ascites or overt heart failure.",{"count":105,"type":21},[24],"Morbidity and mortality of CLD is driven by the extent of liver fibrosis, characterized by scar formation and disruption of the normal liver architecture. HSCs play a central role in liver fibrosis development. When hepatocytes are damaged, HSCs undergo myofibroblast differentiation, transitioning into an activated state. So far, no efficient biomarkers can estimate the degree of HSC activation or reversal across all aetiologies of CLD, although this could be a more sensitive marker than fibrosis measurement which is secondary to HSC activation. This study aims to correlate biomarkers to the fibrosis stage in a larger cohort of patients with CLD across all aetiologies.",[238,239],"Chronic Liver Disease (CLD)","Fibrosis of Liver",[241,242],"chronic liver disease","fibrosis",{"date":244,"type":33},"2026-05-06",{"date":246,"type":21},"2026-05",{"date":225,"type":21},{"name":39,"class":40},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":257,"minAge":258,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":270,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":281},"100595184","screening-for-anal-cancer-in-men-who-have-sex-with-men-using-pre-exposure-prophylaxis-100595184","NCT07029152","Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis","Screening for Anal Cancer in MSM Using PrEP","SCOPE","Inclusion Criteria:\n\n* HIV-uninfected MSM (men who have sex with men) aged 35 years or older.\n* participants must have been using PrEP for at least 3 months.\n* Dutch, English or French speaking and writing\n\nExclusion Criteria:\n\n* Any intervention in the (peri-)anal region within the past 3 months\n* Enema usage within 2 h before sampling\n* Currently undergoing peri-anal topical HPV-treatment\n* HRA in the last year (anal swab or HRA prior to the last year is no exclusion)","MALE","35 Years",{"count":260,"type":21},296,[24],"This study aims to learn more about anal cancer risk in men who have sex with men (MSM) who are using Pre-Exposure Prophylaxis (PrEP) to prevent HIV. Specifically, we want to check how common High-Grade Squamous Intraepithelial Lesions (HSIL) are in this group, how well anal swabs can screen for these lesions, and how having HSIL affects their quality of life. We'll also test if DNA methylation testing can give us extra information about the lesions.\n\nThe main questions the study aims to answer are:\n\n* How common are HSIL in MSM using PrEP?\n* How accurate are anal swabs for detecting HSIL in this group?\n* How does having HSIL affect the quality of life of MSM using PrEP?\n* Can DNA methylation testing help improve our understanding of HSIL in these individuals?\n\nParticipants will:\n\n* Answer questions about their health and quality of life.\n* Have an anal smear collected for testing.\n* Undergo High-Resolution Anoscopy (HRA) to check for HSIL and get a biopsy if deemed necessary.",[264,265,266,267,268,269],"Anal Cancer","Squamous Intraepithelial Lesions","HSIL, High Grade Squamous Intraepithelial Lesions","LSIL, Low-Grade Squamous Intraepithelial Lesions","HPV","Squamous Cell Carcinoma",[271,272,273,274],"HIV prevention","men who have sex with men","pre-exposure prophylaxis (PrEP)","anal cancer",{"date":221,"type":33},{"date":277,"type":33},"2025-09-23",{"date":279,"type":21},"2026-12",{"name":39,"class":40},8,{"id":283,"slug":284,"hasResults":12,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":22,"phases":291,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":41},"100587086","assessment-of-nutrient-absorption-in-enterally-fed-post-intensive-care-unit-patients-using-bomb-calorimetry-do-the-calories-stick-100587086","NCT06923813","Assessment of Nutrient Absorption in Enterally Fed Post-intensive Care Unit Patients Using Bomb Calorimetry: do the Calories Stick","Assessment of Nutrient Absorption in Enterally Fed Post-ICU Patients Using Bomb Calorimetry: do the Calories Stick","STICKY","Inclusion Criteria:\n\n* age of 18 years or older\n* minimum ICU stay of 7 days\n* fully dependent on enteral feeding (nasogastric or PEG-tube)\n* ability of the patient or representative to understand and sign written informed consent in Dutch, French or English\n\nExclusion Criteria:\n\n* known inflammatory bowel disease\n* known malabsorptive gastrointestinal disease\n* history of small bowel resection\n* concomitant use of serotoninergic or sympathomimetic medications (oa. setrone, tryptans, antidepressants, methylphenidate, monoamine oxidase inhibitors, tramadol)",{"count":136,"type":21},[24],"This study focuses on understanding how well patients who have recovered from an ICU stay absorb nutrients when receiving enteral (tube) feeding. Proper nutrition is crucial for recovery, but we don't fully understand how efficiently enteral feeding works in ICU survivors. The study will use advanced techniques like bomb calorimetry to measure the energy content of stool, and indirect calorimetry to measure patients' resting energy expenditure (REE). This will help assess the effectiveness of enteral feeding in these patients, providing valuable information about their metabolic needs and nutritional status.\n\nThe study will also look into the environmental impact of enteral feeding, particularly food waste. By understanding how much of the nutrition is absorbed versus excreted, the study hopes to suggest more sustainable feeding practices and reduce unnecessary waste in hospitals.\n\nKey Goals:\n\n* Primary Goal: Measure how much energy from enteral feeding is absorbed by patients post-ICU by analyzing their stool and energy expenditure.\n* Secondary Goal: Assess how enteral feeding can be made more sustainable, with less waste generated from unused nutritional products.\n\nThis research will help improve nutritional care for ICU patients, enhance recovery, and potentially lead to more environmentally friendly healthcare practices.",[294],"Post-ICU Patients Fully Enterally Fed",[296,297,298],"PEG tube","indirect calorimetry","nasogastric",{"date":221,"type":33},{"date":301,"type":33},"2026-01-08",{"date":303,"type":21},"2028-04-01",{"name":39,"class":40},{"id":306,"slug":307,"hasResults":12,"nctId":308,"briefTitle":309,"officialTitle":309,"acronym":4,"eligibilityCriteria":310,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":311,"enrollmentInfo":312,"targetDuration":4,"studyType":22,"phases":314,"briefSummary":315,"conditions":316,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":318,"startDateStruct":319,"completionDateStruct":321,"leadSponsor":323,"locationsCount":94},"100491564","feasibility-assessment-of-cardiovascular-endurance-training-for-the-symptomatic-improvement-of-irritable-bowel-syndrome-patients-with-a-sedentary-and-non-active-lifestyle-100491564","NCT05680766","Feasibility Assessment of Cardiovascular Endurance Training for the Symptomatic Improvement of Irritable Bowel Syndrome Patients With a Sedentary and Non-active Lifestyle.","Inclusion Criteria:\n\n* Patients aged 18 - 60 years;\n* Fulfilling the ROME IV criteria for Irritable bowel syndrome (IBS);\n* Moderate symptom severity as defined by a IBS-Symptom Severity Scale \\> 175;\n* Sedentary lifestyle defined as SIT-Q-7D \\> 8h\u002Fday;\n* Physically inactive defined as \\\u003C 150min\u002Fweek on the IPAQ score\n\nExclusion Criteria:\n\n* Cardiorespiratory disorder hampering participation in a program of physical exercise as evidenced by the sport + keuringsartsen (SKA) questionnaire.\n* Clinical suspicion of an organic disorder different from IBS (patients can be included when this disorder had been excluded);\n* Known inflammatory bowel disorder;\n* Known intestinal motility disorder;\n* Alcohol (defined as more than 14 U per week) or other substance abuse;\n* Active psychiatric disorder;\n* Known systemic or auto-immune disorder with implication for the GI system;\n* Prior abdominal surgery (with the exception of appendectomy or cholecystectomy more than 6 months ago);\n* Any prior diagnosis of cancer other than basocellular carcinoma;\n* Current chemotherapy;\n* History of gastro-enteritis in the past 8 weeks;\n* Change in diet in the past 8 weeks;\n* Dietary supplements unless taken at a stable dose for more than 8 weeks;\n* Antibiotics, pre-, pro-, post-biotics or any combination during the past 8 weeks;\n* Treatment with neuromodulators (one neuromodulator taken at a stable dose for more than 12 weeks is allowed);\n* Treatment with spasmolytic agents, opioids, loperamide, gelatine tannate or mucoprotect-ants during the past 8 weeks.","60 Years",{"count":313,"type":21},30,[24],"This exploratory study's primary objective is the changes of irritable bowel syndrome (IBS) symptom severity by cardiovascular endurance training (CET) in relation to the baseline sedentary or non-active lifestyle. Secondary endpoints focus on the mechanisms associated with these changes.\n\nThese mechanisms relate to dietary adaptations, changes in anxiety, depressive comorbidity, somatisation, alterations in the gut microbiome or metabolome, body composition and measures of cardiovascular fitness. Virtually all IBS guidelines mention lifestyle modifications as a management option.\n\nResearch on the role of physical activity remains underassessed as compared to the other interventions. Therefore, an exploratory proof-of-concept study will investigate the influence of regular physical exercise on symptoms in a small group of IBS patients. This study will gather data on putative underlying mechanisms related to dietary factors, faecal microbiome and metabolome, mental well-being, body composition and cardiovascular fitness.",[317],"Irritable Bowel Syndrome",{"date":244,"type":33},{"date":320,"type":33},"2023-10-16",{"date":322,"type":21},"2030-01-02",{"name":39,"class":40},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":328,"acronym":4,"eligibilityCriteria":329,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":330,"targetDuration":332,"studyType":79,"phases":4,"briefSummary":333,"conditions":334,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":342,"locationsCount":41},"100402323","predictive-modelling-of-the-intraoperative-train-of-four-tof-ratio-100402323","NCT04518761","Predictive Modelling of the Intraoperative Train-of-Four (TOF) Ratio","Inclusion Criteria:\n\n* Adult patients (18 years old and above) receiving General Anesthesia for noncardiac surgery requiring the use of a neuromuscular blocking agent.\n* Administration of General Anesthesia by means of Total Intravenous Anesthesia technique.\n* Use of Rocuronium as a neuromuscular blocking agent.\n\nExclusion Criteria:\n\n* Use of different types of neuromuscular blocking agents for the same patient within the same surgical procedure\n* Known Neuromuscular diseases\u002Fsyndromes judged to condition accurate neuromuscular monitoring.",{"count":331,"type":21},200,"2 Days","Neuromuscular Blocking Agents (NMBAs) are routinely administered to patients in a multiplicity o anaesthetic settings in order to paralyze and impede (re)active muscular contraction. The availability of monitoring devices allowing an accurate measurement fo the degree of neuromuscular block during anesthesia has raised the standards for a proper evidence-based use of NMBAs.\n\nFor this purpose, one of the most widely used methods is the Train of Four (TOF): transcutaneous application of a series of 4 square-wave supra-maximal electrical stimuli over the course of a nerve of choice (most commonly the ulnar nerve). These are applied at a frequency of 2Hz, and each with a duration of 0.2ms. These stimuli elicit a motor response on the adductor pollicis muscle, which on its turn dictates the adduction of the thumb. The acceleration of this movement can be followed by means of an uni\u002Fmulti-directional accelerometer attached to the thumb. The ratio of the acceleration of the 4th and 1st elicited contractions is called the TOF-Ratio - a clinically and scientifically established method of assessing neuromuscular block recovery. A value of 1 translates a full recovery of the muscular function of a patient. In modern Anesthesia, the bar for deeming a recovery as adequate has been set at a minimum of a TOF-ratio of \\>0.9, with some authors advocating a ratio of 1 as the only acceptable and complications avoiding result.",[335],"Analyse Neuromuscular Monitoring for Developing a Model to Predict TOF Ratio During Anesthesia","2026-04-28",{"date":338,"type":33},"2026-04-29",{"date":340,"type":33},"2020-07-01",{"date":174,"type":21},{"name":39,"class":40},{"id":344,"slug":345,"hasResults":12,"nctId":346,"briefTitle":347,"officialTitle":347,"acronym":348,"eligibilityCriteria":349,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":352,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":362,"leadSponsor":364,"locationsCount":4},"100615236","correlation-between-diagnostic-nerve-block-response-and-cryoneurolysis-outcome-in-chronic-musculoskeletal-disorders-100615236","NCT07289984","Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders","CRYONIC","Inclusion Criteria:\n\n* Be over 18 year old\n* Adults (\\> 18y) with either chronic musculoskeletal pain (\\> 3 months; average NRS \\> 5\u002F10) or painful\u002Ffunctionally limiting spasticity\n* Have a clinical stable condition, \\> 3months\n* Any medications must be maintained on a stable schedule- Able to understand study instructions and provide informed consent (ICF) in French or Dutch.Provide written informed consent\n\nExclusion Criteria:\n\n* Contraindication to cryoneurolysis such as a diagnosis of cryoglobulinemia, paroxysmal cold haemoglobinuria, cold urticaria, Raynaud's disease, any form of peripheral neuropathy, open and or infected wounds of the affected limb\n* Patient's refusal to give consent to the procedure or to use of their data for research purposes.\n* Ongoing local or systemic infection before the procedure.\n* Predominantly neuropathic pain of the upper extremity as assessed with the Pain Detect questionnaire",{"count":351,"type":21},50,[24],"The clinical study is titled the CRYONIC PROTOCOL, which stands for Cryotherapy for Neurolysis In Chronic Pain. It is structured as a prospective, multi-cohort observational study.\n\nPurpose of the Study:\n\nThe overarching purpose of the CRYONIC PROTOCOL study is to assess the Correlation Between Diagnostic Nerve Block Response and Cryoneurolysis Outcome in Chronic Musculoskeletal Disorders. The study focuses on evaluating the effectiveness of ultrasound-guided peripheral nerve cryoneurolysis, a minimally invasive technique that uses extreme cold to induce temporary nerve blocks, for patients with treatment-resistant chronic musculoskeletal pain.\n\nThe study also seeks to determine if cryoneurolysis itself leads to meaningful improvements in both pain intensity and functional ability in the included patient cohorts.",[355,356,357],"Chronic Musculoskeletal Pain","Cryo Analgesia","Cryoablation","2026-04-21",{"date":360,"type":33},"2026-04-27",{"date":90,"type":21},{"date":363,"type":21},"2031-08-01",{"name":39,"class":40},{"id":366,"slug":367,"hasResults":12,"nctId":368,"briefTitle":369,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":74,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":79,"phases":4,"briefSummary":375,"conditions":376,"keywords":379,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":358,"lastUpdatePostDateStruct":381,"startDateStruct":383,"completionDateStruct":385,"leadSponsor":386,"locationsCount":94},"100603296","mitochondrial-function-in-peripheral-blood-mononuclear-cells-muscle-and-skin-of-long-covid-patients-100603296","NCT07134673","Mitochondrial Function in Peripheral Blood Mononuclear Cells, Muscle, and Skin of Long COVID Patients","Mitochondrial Oxygen Consumption and Substrate Utilisation In Vitro in Peripheral Blood Mononuclear Cells, and In Vivo on Muscle and Skin in Long COVID Patients and Convalescent Individuals: A Case-Control and Diagnostic Accuracy Study","MitoLoCo","Individuals with long COVID:\n\nInclusion criteria:\n\n* Long COVID diagnosis, based on the WHO definition;\n* Presence of long COVID symptoms for a minimum of 6 months.\n* History of confirmed or documented SARS-CoV-2 infection.\n* Adult (≥18 years of age).\n* Post-COVID-19 Functional Status Scale grade 2-4, while they had a grade 0 before the SARS-CoV-2 infection.\n\nExclusion criteria:\n\n* Pre-existing chronic diseases potentially affecting the functional status scale.\n* Treatment with metabolism altering drugs.\n* \\> 10 standard units of alcohol (10 grams of alcohol\u002Fglass) per week.\n* Unable to understand oral and written instructions in Dutch, French or English.\n* Allergies to medical adhesive bandages.\n* Porphyria and other skin conditions aggravated by sunlight.\n\nConvalescent individuals\n\nInclusion criteria:\n\n* History of confirmed or documented SARS-CoV-2 infection.\n* Complete recovery after the SARS-CoV-2 infection, no history of long COVID based on the WHO definition;\n* Post-COVID-19 Functional Status Scale \\[2\\] grade 0 both before the infection and currently.\n* Adult (≥18 years of age).\n\nExclusion criteria:\n\n* Pre-existing chronic non-communicable diseases (e.g. hypertension, chronic respiratory diseases, diabetes).\n* Treatment with metabolism altering drugs.\n* \\> 10 standard units of alcohol (10 grams of alcohol\u002Fglass) per week.\n* Unable to understand oral and written instructions in Dutch, French or English.\n* Allergies to medical adhesive bandages.\n* Porphyria and other skin conditions aggravated by sunlight.",{"count":374,"type":21},54,"Mitochondria are structures inside cells that are responsible for producing energy from nutrients through a series of steps, using oxygen. To have an idea of how well the mitochondria can produce energy, we can measure how much oxygen they use. The goal of this study is to:\n\n1. To compare the oxygen use between people with long COVID and people who completely recovered after COVID-19, using three techniques that measure the oxygen use in blood cells, on the skin and in the muscle\n2. To test how similar these three techniques are in measuring the oxygen used in the three different tissues\n\nParticipants will:\n\n* Complete surveys,\n* Wear an activity tracker (7 days),\n* Undergo several non-invasive tests, and\n* Donate a blood sample The study will take place in UZ Brussel hospital and will take 2 study visits, approximately 7 days apart.",[377,378],"Long COVID","Post-COVID-19 Condition",[380],"mitochondrial dysfunction",{"date":382,"type":33},"2026-04-22",{"date":384,"type":33},"2026-01-21",{"date":223,"type":21},{"name":39,"class":40},{"id":388,"slug":389,"hasResults":12,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":12,"sex":257,"minAge":18,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":22,"phases":397,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":403,"lastUpdatePostDateStruct":404,"startDateStruct":406,"completionDateStruct":408,"leadSponsor":410,"locationsCount":94},"100471067","autologous-testicular-tissue-transplantation-100471067","NCT05414045","Autologous Testicular Tissue Transplantation","Autologous Testicular Tissue Transplantation for Fertility Restoration","The eligible patients opted as a prepubertal boy to enroll in the fertility preservation program and on the moment of cancer diagnosis or hematological disorder, their parents have agreed to cryopreserve testicular tissue for later autologous transplantation.\n\nInclusion Criteria:\n\n* At least 18 years old\n* In case of female partner, age \\\u003C 43 year\n* Absence of spermatozoa that can be used for ICSI on 2 semen analyses\n* Normal standardised preliminary and preoperative bloodsampling results\n* Complete remission of the oncological or hematological disease\n* Approval of the treating oncologist or other specialist in case of non-oncological disease as reason for the testicular tissue preservation as a child\n* Risk for presence of malignant cells in testicular tissue is negligible (according to multidisciplinary assessment)\n* Presence of spermatogonial stem cells (positive MAGE staining) in one or two of the thawed fragments (If absence of spermatogonial stem cells in two of the thawed fragments, the case will be discussed multidisciplinary)\n* Written informed consent for the transplantation of cryopreserved testicular tissue and follow-up after the procedure and of children born eventually after this procedure\n\nExclusion criteria:\n\n* Risk for presence of malignant cells in the testicular tissue\n* Contra-indication for surgery\n* Contra-indication for pregnancy in the female partner\n* BMI \\> 32\n* Heavy smoking (≥10 cigarettes\u002Fday)\n* Instable psychological condition","50 Years",{"count":396,"type":21},5,[24],"Freezing testicular tissue of prepubertal boys is a method for preserving spermatogonial stem cells in case of imminent gonadotoxic treatment during childhood. In case of total azoospermia or absence of spermatozoa that can be used for intra-cytoplasmic injection (ICSI) in adulthood, the investigators intend to perform the first in men autologous testicular tissue transplantation to restore fertility.",[400,401,402],"Cancer","Sickle Cell Thalassemia","Hematologic Diseases","2026-04-20",{"date":405,"type":33},"2026-04-23",{"date":407,"type":33},"2024-11-22",{"date":409,"type":21},"2030-10-29",{"name":39,"class":40},{"id":412,"slug":413,"hasResults":12,"nctId":414,"briefTitle":415,"officialTitle":416,"acronym":417,"eligibilityCriteria":418,"healthyVolunteers":74,"sex":75,"minAge":18,"maxAge":4,"enrollmentInfo":419,"targetDuration":4,"studyType":22,"phases":421,"briefSummary":422,"conditions":423,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":429,"leadSponsor":431,"locationsCount":4},"100633998","the-aim-of-this-study-is-to-gain-insight-into-the-occurrence-of-irritable-bowel-symptoms-during-ovarian-stimulation-in-individuals-with-pcos-and-in-women-who-wish-to-freeze-their-eggs-this-study-uses-questionnaires-100633998","NCT07533968","The Aim of This Study is to Gain Insight Into the Occurrence of Irritable Bowel Symptoms During Ovarian Stimulation in Individuals With PCOS and in Women Who Wish to Freeze Their Eggs. This Study Uses Questionnaires.","Fertility Treatment: Impact on Symptoms of Irritable Bowel Syndrome","FIBS","Inclusion Criteria:\n\n* Diagnosis of PCOS according to the 2004 Rotterdam criteria (only for the PCOS group and not for the social freezing group)\n* Initiating their first cycle of IVF treatment (PPOS and freeze only protocol)\n* Nulliparous\n* ≥ 18 years\n* Willing to participate in the study\n* Understanding Dutch, French or English\n\nExclusion Criteria:\n\n* \\- Known inflammatory bowel disorder\n* Known major intestinal bowel disorder\n* Known systemic or auto-immune disorder with implication for the GI system\n* History of abdominal surgery (appendectomy and cholecystectomy allowed if \\>6 months earlier)\n* History of gastro-enteritis in the past 6 weeks",{"count":420,"type":21},120,[24],"This exploratory study investigates the impact of fertility treatments on symptoms of irritable bowel syndrome (IBS) in women. Specifically, the study focuses on two groups:\n\n* Women with polycystic ovary syndrome (PCOS) who are starting their first IVF cycle.\n* Women who choose social freezing (freezing eggs for social reasons).\n\nBackground and Rationale PCOS is an endocrine disorder with hormonal and metabolic abnormalities associated with reduced fertility. There are four PCOS phenotypes, of which phenotypes A and B are the \"classic\" forms. Social freezing is becoming increasingly popular as an option for women without a partner who want to preserve their fertility.\n\nIBS is a common gastrointestinal disorder involving motility disorders and a disturbed gut-brain axis. There is an increased risk of anxiety and depression in IBS patients. Women with PCOS have a twofold increased risk of developing IBS. However, little is known about the effect of hormonal fertility treatments on IBS symptoms.\n\nObjectives\n\n* Primary objective: To investigate whether fertility treatments influence the prevalence and severity of IBS symptoms.\n* Secondary objective: To investigate this change in IBS prevalence and severity in relation to:\n* Changes in anxiety and depression scores.\n* Changes in general gastrointestinal complaints.\n* Subgroup analyses based on:\n* Type of stimulation\n* Duration of desire to have children\n* Ethnicity\n* PCOS type\n* Hormonal and ultrasound response\n\nStudy design The study is a prospective, interventional exploratory study in which participants complete questionnaires before and after the hormonal stimulation phase.\n\n* Start date : March 1, 2026\n* End date of data collection: February 2027\n* Participation locations: Fertility Clinic UZ Brussels\n* Target sample size: 120 women (60 per group)\n\nData collected\n\nBefore treatment:\n\n* Demographics (height, weight, ethnicity)\n* Medical history related to fertility\n* PCOS phenotype (in study arm)\n\nAfter treatment:\n\n* Hormonal values (FSH, LH, estrogen, progesterone)\n* Number of follicles on ultrasound\n* Number of eggs collected\n\nQuestionnaires:\n\n* IBS-SSS (IBS symptom severity)\n* Rome IV and III criteria (IBS diagnosis)\n* GSRS (general GI symptoms)\n* PHQ-9 (depression)\n* GAD-7 (anxiety)\n\nMeasuring instruments\n\n* Rome IV and III criteria: Diagnosis of IBS based on frequency and nature of abdominal pain and changes in bowel movements.\n* IBS-SSS: Five dimensions of IBS symptoms, score between 0 and 500.\n* GSRS: General gastrointestinal complaints in five domains.\n* PHQ-9 and GAD-7: Validation instruments for depression and anxiety.\n\nData management\n\n* Data is collected manually using paper questionnaires.\n* Data is then entered into RedCap.\n* Analysis is performed using SPSS.\n* Strict compliance with GDPR and confidentiality guidelines.\n\nStatistical Analysis\n\n* Logistic regression: To determine the likelihood of meeting the Rome criteria before and after treatment.\n* Multiple linear regression: To identify factors that influence change in IBS-SSS scores.\n* Model selection: Based on AIC (Akaike Information Criterion).\n* Separate analyses for PCOS and social freezing groups.",[424],"PCOS (Polycystic Ovary Syndrome)","2026-04-13",{"date":427,"type":33},"2026-04-16",{"date":403,"type":21},{"date":430,"type":21},"2027-05-01",{"name":39,"class":40},{"id":433,"slug":434,"hasResults":12,"nctId":435,"briefTitle":436,"officialTitle":437,"acronym":438,"eligibilityCriteria":439,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":442,"briefSummary":443,"conditions":444,"keywords":447,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":451,"startDateStruct":453,"completionDateStruct":455,"leadSponsor":457,"locationsCount":94},"100606478","evaluating-the-added-benefit-of-osteopathic-care-to-a-flexi-fodmap-diet-in-fibromyalgia-patients-with-irritable-bowel-syndrome-100606478","NCT07176078","Evaluating the Added Benefit of Osteopathic Care to a Flexi-FODMAP Diet in Fibromyalgia Patients With Irritable Bowel Syndrome","Evaluating the Added Benefit of Osteopathic Care to a Flexi-FODMAP Diet in Fibromyalgia Patients With Irritable Bowel Syndrome: a Randomized Sham-controlled Trial","POISE-IBS-RCT","Inclusion Criteria:\n\nThis study includes participants who meet the following criteria:\n\n1. are over 18 years old;\n2. have a diagnosis of IBS by a medical doctor according to the Rome IV criteria and have an IBS-SSS score of ≥175 (indicating moderate to severe IBS symptoms);\n3. have a medical diagnosis of fibromyalgia or meet the 2016 American College of Rheumatology criteria, characterized by chronic (≥3 months) widespread pain(i.e., a Widespread Pain Index(WPI) score of ≥7 with a Symptom Severity Score of ≥5, or a WPI score of 4-6 with a Symptom Severity Score ≥9 on the Widespread Pain Index).\n\nParticipants will be allowed to use probiotic products and follow a lactose-reduced diet, as long as they kept their usual intake throughout the study, unless a further reduction in lactose was recommended for those assigned to diet therapy. IBS medications, including antidepressants, will be allowed if used consistently at a stable dose for at least 2-3month prior to inclusion. Additionally, participants will need to be willing to adjust their current dietary habits in order to take part in the study.\n\nExclusion Criteria:\n\nThis study excludes participants who meet any of the following criteria:\n\n1. have other gastrointestinal disorders (e.g., inflammatory bowel disease, celiac disease) that could explain the current symptoms;\n2. have diseases affecting gastrointestinal function, including a history of bariatric surgery;\n3. have allergies or food hypersensitivity (other than lactose intolerance);\n4. have any major dietary restrictions or food allergies;\n5. are pregnant or planning pregnancy during the trial (within the next seven months);\n6. have a BMI ≤18 kg\u002Fm²; or 7) have received osteopathic care for IBS and\u002For are already following the FODMAP dietary intervention.",{"count":441,"type":21},96,[24],"Dietary modifications are often recommended as first-line treatment for irritable bowel syndrome, with the FODMAP diet being the most effective intervention to improve global gastrointestinal symptoms. Due to the heterogeneity of symptoms, patients often seek complementary or alternative therapies. This randomized clinical trial aims to determine whether osteopathic care provides additional improvement in gastrointestinal symptoms compared to sham osteopathic care, when both are combined with a flexible FODMAP diet. The trial will also assess the safety and tolerability of osteopathic care.\n\nThe main questions it aims to answer are:\n\nDoes osteopathic care reduce IBS symptom severity more than sham osteopathic care?\n\nDoes osteopathic care improve pain, quality of life, anxiety, fatigue, work productivity, and gut microbiota compared to sham osteopathic care?\n\nDo participants adhere to the flexible FODMAP diet and osteopathic care, and are the effects of osteopathic care maintained at 3- and 6-months post-intervention?\n\nCan pretreatment factors, such as sociodemographic characteristics, IBS severity, predominant symptoms, psychological state, or gut microbiota composition, predict response to osteopathic care?\n\nWhat adverse effects occur with osteopathic care compared to sham care?\n\nParticipants will:\n\nVisit the osteopathy clinic to receive four sessions of real or sham osteopathic care\n\nComplete online assessments before and after the intervention, and at 3- and 6-months post-intervention\n\nProvide stool samples before and after the four osteopathic or sham sessions\n\nKeep a three-day food diary and a ten-day stool diary before and after the intervention, and at 3- and 6-months post-intervention",[445,446],"Irritable Bowel Syndrome (IBS)","Fibromyalgia (FM)",[448,317,449,450],"Osteopathic Care","Fibromyalgia","FODMAP Diet",{"date":452,"type":33},"2026-04-17",{"date":454,"type":33},"2026-01-01",{"date":456,"type":21},"2027-06",{"name":39,"class":40},{"id":459,"slug":460,"hasResults":12,"nctId":461,"briefTitle":462,"officialTitle":463,"acronym":4,"eligibilityCriteria":464,"healthyVolunteers":74,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":465,"targetDuration":467,"studyType":79,"phases":4,"briefSummary":468,"conditions":469,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":481,"leadSponsor":483,"locationsCount":94},"100634172","deep-learning-framework-for-continuous-depth-of-anesthesia-forecasting-100634172","NCT07536230","Deep Learning Framework for Continuous Depth of Anesthesia Forecasting","Validation of a Deep Learning Framework for Continuous Forecasting of Pharmacodynamic Responses and Physiological Trajectories During General Anesthesia","Inclusion Criteria:\n\n* Patients scheduled for elective surgery requiring general anesthesia.\n* Procedures requiring continuous depth of anesthesia monitoring (BIS).\n\nExclusion Criteria:\n\n\\- Procedures where the primary anesthetic plan does not involve continuous electronic data capture.",{"count":466,"type":21},115,"1 Day","The integration of Artificial Intelligence (AI) in anesthesiology offers the potential to shift patient monitoring from reactive to predictive. Deep learning architectures, specifically Long Short-Term Memory (LSTM) networks, excel at processing complex, time-series data to forecast future clinical states.\n\nWhile standard PK\u002FPD models (such as the state of the art Eleveld model for Propofol and Remifentanil) estimate target-site drug concentrations (Ce), they do not account for real-time, patient-specific dynamic responses. This study aims to deploy an AI framework designed to predict future physiological states.",[470,471,472,473,474,475,476,477],"BIS","BIS-EEG","Artifical Intelligence","Intraoperative","Machine Learning","Anesthesia","Anesthesia Awareness","Predictive Model","2026-04-10",{"date":452,"type":33},{"date":121,"type":21},{"date":482,"type":21},"2026-09-01",{"name":39,"class":40},{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":492,"targetDuration":4,"studyType":22,"phases":494,"briefSummary":495,"conditions":496,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":501,"completionDateStruct":503,"leadSponsor":505,"locationsCount":94},"100627453","phase-2-a-phase-ii-clinical-trial-on-neo-adjuvant-pembrolizumab-in-patients-with-pt3b-t4ab-cn0m0-melanoma-100627453","NCT07448831","A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a\u002Fb cN0M0 Melanoma.","A Phase 2 Clinical Trial on Neoadjuvant Pembrolizumab in Patients Diagnosed With High-risk Melanoma Without Clinical Evidence of Metastatic Dissemination.","NeoSenti","Inclusion Criteria:\n\n≥ 18 years of age on the day of signing the informed consent.\n\nHistologically confirmed high risk primary cutaneous pT1b-4b melanoma High risk primary melanoma is defined in this study as the following AJCC8 T-stages:\n\n* pT1b-3a, with a poor prognostic score on the Merlin™ test (\"Merlin™ high risk\");\n* pT3b-4b, irrespective of their Merlin™ test result\n\nAmendable to sentinel lymph node biopsy.\n\nNo evidence of metastatic dissemination as demonstrated by PET\u002FCT, ultrasound of the draining lymph node basin, and clinical examination.\n\nNo prior exposure to systemic treatment for melanoma (adjuvant or curative).\n\nEastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1 or 2 assessed within 7 days prior to the first dose of study treatment.\n\nAdequate baseline organ function as defined by local institutional standards.\n\nWomen:\n\n* Female patients must be surgically sterile or be postmenopausal (A postmenopausal state is defined as no menses for 12 months without an alternative medical cause).\n* If a female patient is a woman of childbearing potential (WOCBP) they must agree to use highly effective contraception measures during the period of therapy, which should be continued for at least 4 months following the last dose of pembrolizumab as indicated in the SmPC. A list of highly effective contraceptive measures is included in appendix 1 All female patients with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment and pregnancy testing should be conducted within 24h prior to the first dose of immune checkpoint inhibitors and thereafter monthly until 4 months following the last dose study treatment.\n* Should not be breastfeeding at screening or during study treatment.\n\nMen with a female partner of childbearing potential must agree to use highly effective contraception from 14 days prior to administration of the first dose of study treatment or have either had a prior vasectomy, throughout the treatment period, and for 16 weeks after the last dose of study treatment.\n\nCapable of providing documented informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.\n\nExclusion Criteria:\n\nPatients with uveal melanoma, mucosal melanoma and melanoma of unknown primary origin.\n\nActive autoimmune disease requiring systemic treatment.\n\nPatients with a history of previous malignancies (except non-melanoma skin cancers, and the following in situ cancers: gastric, colon, cervical\u002Fdysplasia, melanoma, or breast) are excluded unless a complete remission was achieved at least 3 years prior to screening and no additional therapy is required or anticipated to be required during the study period.\n\nKnown Human Immunodeficiency Virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection. Exception: subjects with laboratory evidence of cleared HBV and HCV infection will be permitted.\n\nAny serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), psychiatric disorders, or other conditions that could interfere with the subject's safety, obtaining informed consent, or compliance with study procedures.\n\nActive infection at the time of screening (e.g. wound infection).\n\nKnown immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study treatment, or excipients.\n\nHistory of organ allograft.\n\nPatients who have previously been exposed to checkpoint inhibitors.\n\nPrior transplantation of human cells, tissues and organs (e.g. liver transplant) or candidates for any type of transplantation.\n\nHistory or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate, in the opinion of the treating investigator.\n\nKnown psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n\nAny contra-indication for evaluation by whole body 18F-FDG-PET\u002FCT or MRI.",{"count":493,"type":21},49,[138],"This study, called NeoSenti, is exploring whether giving one dose of the immunotherapy drug pembrolizumab before surgery can help the immune system fight melanoma more effectively. The study includes adults with high-risk melanoma who do not show any signs of the cancer having spread on scans. Participants receive a single infusion of pembrolizumab six weeks before their scheduled sentinel lymph node biopsy. The goal is to see if this early treatment can reduce or eliminate tiny cancer cells that might already be in the lymph nodes but are too small to detect.\n\nAfter surgery, patients whose melanoma stage normally requires further treatment will continue with standard immunotherapy for one year. Others will move directly into follow-up care. All participants are monitored closely for five years with regular scans, blood tests, and check-ups to watch for any signs of recurrence and to ensure their safety.",[497],"Melanoma (Skin Cancer)","2026-03-05",{"date":500,"type":33},"2026-03-09",{"date":502,"type":33},"2025-04-17",{"date":504,"type":21},"2029-12",{"name":39,"class":40},{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":17,"minAge":76,"maxAge":514,"enrollmentInfo":515,"targetDuration":4,"studyType":22,"phases":517,"briefSummary":518,"conditions":519,"keywords":522,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":533,"completionDateStruct":535,"leadSponsor":537,"locationsCount":94},"100626898","partial-range-of-field-iols-in-dmek-enabled-procedures-100626898","NCT07441616","Partial Range Of Field IOLs in DMEK-Enabled Procedures","A Feasibility Study Evaluating Visual Outcomes of Extended Partial Range of Field Refractive Intraocular Lenses in Patients Undergoing Combined Cataract Surgery and Descemet Membrane Endothelial Keratoplasty (Triple DMEK)","PROFIDE","Inclusion Criteria:\n\n* Patients with bilateral cataract grade greater than II, according to the Lens Opacities Classification System III (LOCS III) , combined with FECD displaying clinical or subclinical corneal edema or displaying visual disturbing guttae with at least Krachmer grade 3\n* Patients aged between 40 and 90 years\n* Capacity to read and to understand the study information and to provide informed consent, as well as Patient Reported Spectacle Independence Questionnaire (PRSIQ) and Patient Reported Visual Symptom Questionnaire (PRVSQ)\n* Patients willing and capable to attend the 6-month follow-up appointment\n\nExclusion Criteria:\n\n* history of ocular surgery\n* corneal scars\n* macular disease revealed by pre-surgical macular Optical Coherence Tomography (OCT),\n* opticopathy\n* glaucoma with reduced sensitivity of visual field\n* uveitis\n* amblyopia\n* axial length \\\u003C22mm or \\>25mm,\n* scotopic pupil size \\>5mm,\n* central corneal thickness \\>700microns,\n* corneal astigmatism \\>1 diopters (D) on biometry\n* irregular astigmatism (RMS HOA 3mm pupil \\>0.3)\n* angle kappa \\>0.3mm ((chord µ measured with Pentacam HR; Oculus, Wetzlar, Germany)","90 Years",{"count":516,"type":21},10,[24],"Study Overview\n\nThis study aims to evaluate the visual outcomes, quality of vision, and patient satisfaction after receiving an extended range PRoF intraocular lens (IOL) during triple Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. This surgery is typically performed to treat patients with both corneal endothelial dysfunction and cataracts. By testing a newer IOL, the PureSee™ extended PRoF IOL, this study hopes to improve the way ophthalmologists plan surgeries and select IOLs for these patients, ultimately helping surgeons optimize the results and expand the options available for people undergoing this procedure.\n\nPurpose of the Study\n\nThe goal of this study is to evaluate how well the PureSee™ IOL works in terms of intermediate visual acuity (how well participants can see things at an arm's length). The investigators will also measure the quality of vision, satisfaction, and whether participants need glasses after surgery.\n\nThe investigators have set the following goals for this study:\n\nPrimary Goal:\n\nTo measure how well patients can see intermediate distances (uncorrected intermediate visual acuity, or UIVA) after receiving the PureSee™ IOL during triple DMEK surgery.\n\nSecondary Goals:\n\nTo understand how independent patients are from glasses after surgery.\n\nTo measure patients' uncorrected and best-corrected visual acuity (sharpness of vision) at distance, intermediate, and near vision after surgery.\n\nTo evaluate the uncorrected defocus curve (how the vision of participants changes when focusing at different distances).\n\nTo measure contrast sensitivity (how well participants can see in low-light conditions or with subtle contrasts).\n\nWho Can Join This Study?\n\nTo participate in this study, participants need to:\n\nBe undergoing triple DMEK surgery for endothelial dysfunction and cataract at the time of enrollment.\n\nBe eligible to receive an extended range of vision IOL as part of the procedure.\n\nThis study is looking for patients who are interested in understanding how new IOL technology might improve their postoperative vision quality and reduce their dependence on glasses.\n\nWhat Will Happen During the Study?\n\nParticipants will have their visual outcomes and satisfaction measured at specific times following surgery. This includes:\n\nTesting uncorrected and best-corrected visual acuity at several distances (distance, intermediate, and near).\n\nCompleting a survey about how satisfied they are with their vision and how often they need glasses or contact lenses.\n\nUndergoing testing to measure contrast sensitivity (how well participants can see in low-light conditions).\n\nWhy Is This Study Important?\n\nThe results of this study will help doctors make better decisions about which IOLs to use during triple DMEK surgery. By evaluating the PureSee™ extended PRoF IOL, the investigators hope to expand options for patients and potentially improve visual outcomes and postoperative satisfaction. Ultimately, this study could help improve the quality of life for patients who have both cataracts and endothelial dysfunction.\n\nStudy Duration\n\nParticipants can expect to undergo their last assessment 6 months post-surgery to track their progress.",[520,521],"Cataract","Fuchs Endothelial Corneal Dystrophy",[523,524,525,526,527,528,529],"dmek","triple","endothelial keratoplasty","fuchs","cataract","edof iol","partial range of field iol","2026-02-23",{"date":532,"type":33},"2026-03-02",{"date":534,"type":21},"2026-03",{"date":536,"type":21},"2028-02",{"name":39,"class":40},{"id":539,"slug":540,"hasResults":12,"nctId":541,"briefTitle":542,"officialTitle":543,"acronym":544,"eligibilityCriteria":545,"healthyVolunteers":74,"sex":17,"minAge":467,"maxAge":546,"enrollmentInfo":547,"targetDuration":4,"studyType":22,"phases":549,"briefSummary":550,"conditions":551,"keywords":555,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":563,"lastUpdatePostDateStruct":564,"startDateStruct":566,"completionDateStruct":568,"leadSponsor":570,"locationsCount":94},"100619678","preventive-effect-of-a-dietary-supplement-with-two-probiotic-limosilactobacillus-reuteri-strains-on-excessive-crying-and-colic-in-healthy-newborns-100619678","NCT07347743","Preventive Effect of a Dietary Supplement With Two Probiotic Limosilactobacillus Reuteri Strains on Excessive Crying and Colic in Healthy Newborns.","Double-blind, Randomized Placebo-controlled Trial for the Preventive Effect of Limosilactobacillus Reuteri (L. Reuteri) on Excessive Crying and Colic in Healthy Infants.","ProtectPrevent","Inclusion Criteria:\n\n1. Infant is born at the maternity ward of UZ Brussel with a gestational age of ≥37 weeks.\n2. Infant is healthy at the time of pre-examination.\n3. Infant is aged between 1 and 14 days old at the time of inclusion.\n4. Legal guardian(s) are able and willing to follow the study instructions\n5. Infant is suitable for participation in the study according to the investigator\u002F study personnel\n6. Legal guardian(s) willing to refrain products containing probiotics for their infant, from baseline (visit 1) throughout the study period (visit 3).\n7. Informed written consent given by parent \u002F legal guardian\n\nExclusion Criteria:\n\n1. No legal guardian's command of any local language\n2. Infant with a major congenital anomaly (i.e. anal atresia, trisomy 21) or suspicion of any chronic disorder or disease (i.e. Hirschsprung's disease, metabolic disorder)\n3. Infant is suffering from congenital or acquired immunodeficiency\n4. Infant is suffering from an infection at the time of pre-examination or previous 7 days\n5. Infant is admitted post-partum to the neonatal intensive care unit\n6. Infant is not suitable for participation in the study according to the study personnel´s opinion","14 Days",{"count":548,"type":21},768,[24],"This study aims to demonstrate that a dietary supplement, which contains two strains of the probiotic L. reuteri is safe, well tolerated and able to reduce the incidence of colic and excessive crying\u002Ffussiness in healthy infants. Additionally, the study aims to investigate if children with this probiotic supplement have better stool characteristics and a more beneficial composition of the fecal and skin flora than children given a placebo during the first 3 months of life.",[552,553,554],"Colic","Healthy Infants","Eczema Atopic Dermatitis",[556,557,558,559,560,561,562],"Preventive effect","Limosilactobacillus reuteri","L. reuteri","crying","colic","healthy infants","newborns","2026-02-16",{"date":565,"type":33},"2026-02-19",{"date":567,"type":33},"2026-01-31",{"date":569,"type":21},"2028-12",{"name":39,"class":40},{"id":572,"slug":573,"hasResults":12,"nctId":574,"briefTitle":575,"officialTitle":576,"acronym":577,"eligibilityCriteria":578,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":579,"targetDuration":4,"studyType":22,"phases":580,"briefSummary":581,"conditions":582,"keywords":585,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":589,"lastUpdatePostDateStruct":590,"startDateStruct":592,"completionDateStruct":594,"leadSponsor":596,"locationsCount":94},"100622801","diagnostic-accuracy-of-ecg-less-gated-cardiac-ct-in-resuscitated-cardiac-arrest-survivors-without-st-elevation-myocardial-infarction-100622801","NCT07388342","Diagnostic Accuracy of ECG-less Gated Cardiac CT in Resuscitated Cardiac Arrest Survivors Without ST Elevation Myocardial Infarction","Diagnostic Accuracy of ECG-less Gated Cardiac CT in Resuscitated Cardiac Arrest Survivors","OPEN CCTArrest","* Inclusion:\n\n  * Adults (≥18 years) with sustained return of spontaneous circulation (ROSC) following in\u002Fout-of-hospital cardiac arrest.\n  * Informed consent from patient or representative obtained before invasive coronary angiography.\n* Exclusion\n\n  * Patients on VA-ECMO\n  * ACS STEMI or STEMI \"equivalent\"\n\n    * New left\u002Fright bundle branch block\n    * ST segment depression in leads V1-V3, when the terminal T wave is positive and concomitant ST-segment elevation ≥ 0,5mm recorded in leads V7-V9 (posterior MI)\n    * ST-segment elevation in V7-V9 (posterior MI) or V3R-V4R (RV MI)\n  * ACS NSTEMI with persistent ST depression despite optimal therapy, suggesting ongoing myocardial ischemia, with indication for an urgent ICA according to the treating physician.\n  * Hemodynamic\u002Felectrical instability precluding CT imaging (as perceived by the treating physician)\n  * Life-threatening arrhythmia potentially caused by acute myocardial ischemia\n  * Absolute contraindications to iodinated contrast\n  * Patients with a known non-cardiac cause of cardiac arrest (e.g., traumatic brain injury, overt hemorrhage, asphyxia\u002Fsevere hypoxia due to known lung disease, trauma, severe metabolic\u002Felectrolyte derangement, or intoxication) as perceived by the treating physician, where chest CT is considered unnecessary.\n  * Known or likely pregnancy or lactation\n  * Severe bleeding issue (as perceived by the treating physician) precluding heparin administration during radial access coronary angiography.\n  * Prior coronary intervention (stent implantation\u002FCABG).\n  * CT findings indicating a condition that precludes coronary angiography in the short term.\n  * Patients with end-of-life care pathways.\n  * Participation in another intervention study interfering with the research questions in OPEN CCT Arrest.",{"count":313,"type":21},[24],"In a significant portion of patients surviving a cardiac arrest, the event is caused by a myocardial infarction (a narrowing or blockage of one or more blood vessels that supply blood to the heart, the coronary arteries). In some people, this is immediately evident from basic tests; in others, it is more difficult to predict with the currently available tests whether this (or something else) caused the cardiac arrest. We investigate a technique that allows us to also assess the coronary arteries on the CT scan that is performed in patients surviving a cardiac arrest. The coronary angiography is currently the best exam we have for examining the coronary arteries, but it has some disadvantages. Compared to the CT scan, it takes more time, needs a more complex access to the blood vessels, and has some rare but relevant possible complications. The major advantage of the coronary angiography is that there is the possibility of immediate treatment of a narrowed\u002Fblocked blood vessel of the heart. The current guidelines advice an urgent coronary angiography when a clear myocardial infarction is suggested on the electrocardiogram, but not when there is no clear indication of myocardial infarction. Nonetheless, a relevant portion (more or less 40%) of the patients without a clearly abnormal electrocardiogram, still have an important problem in the blood vessels of the heart. We aim to determine whether the CT scan provides accurate information about the condition of the blood vessels of the heart. The CT scan was already well examined for this purpose before, but in the currently conventional way it needs preparation with extra monitoring and administration of medication, which would lead to loss of precious time and potentially dangerous side effects of these drugs in this critical situation. For that reason, a new software modality was developed that allows us to examine the coronary arteries in the same CT scan, without need for additional monitoring or medication administration. It does not need additional contrast administration (the dye necessary for optimal evaluation of some diseases).\n\nThe goal of this study is to determine whether this new technique gives us the correct information about the coronary arteries. This means we acquire the images of the heart in the same scan, and verify the results with the conventional coronary angiography. If the technique provides accurate information, it could lead to a better selection of patients we need to urgently refer for a coronary angiography and to defer the exam in those who have normal coronary arteries on the scan.",[583,584],"Cardiac Arrest (CA)","Myocardial Infarction (MI)",[586,587,588],"Cardiac Arrest","Myocardial Infarction","Coronary Computed Tomography Angiography (CCTA)","2026-01-29",{"date":591,"type":33},"2026-02-05",{"date":593,"type":33},"2025-09-01",{"date":595,"type":21},"2027-12-01",{"name":39,"class":40},{"id":598,"slug":599,"hasResults":12,"nctId":600,"briefTitle":601,"officialTitle":602,"acronym":603,"eligibilityCriteria":604,"healthyVolunteers":74,"sex":17,"minAge":605,"maxAge":606,"enrollmentInfo":607,"targetDuration":4,"studyType":22,"phases":609,"briefSummary":610,"conditions":611,"keywords":619,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":624,"lastUpdatePostDateStruct":625,"startDateStruct":627,"completionDateStruct":629,"leadSponsor":631,"locationsCount":94},"100617272","birth-cohort-development-of-ige-autoantibodies-in-newborns-with-high-risk-of-atopic-dermatitis-100617272","NCT07316465","Birth Cohort: Development of IgE Autoantibodies in Newborns With (High Risk of) Atopic Dermatitis","Development of IgE Autoantibodies in Newborns With Atopic Dermatitis (DIANA) Birth Cohort","DIANA","Inclusion Criteria:\n\nNewborns who are planned to be born at the maternity ward of UZ Brussel with the following criteria:\n\n* 400 newborns with high-risk for AD-development (at least 1 parent or sibling with physician diagnosed atopic dermatitis AND\u002FOR asthma AND\u002FOR allergic rhinitis)\n* 100 newborns with low-risk for AD-development (no parents or siblings with history of atopic dermatitis AND\u002FOR asthma AND\u002FOR allergic rhinitis)\n\nExclusion Criteria:\n\n* Newborns not born at the maternity ward of UZ Brussel\n* Parents with a poor understanding of Dutch, French or English\n* Newborns who are admitted post-partum to the neonatal intensive care unit (gestational age \\\u003C34 weeks) or with medical complications\n* Newborns with severe genetic abnormalities\u002Fbirth defects\n* Newborns whose parents will not be able to attend the study visits for a period of 2 years (location, working hours)","1 Hour","24 Months",{"count":608,"type":21},500,[24],"Previous research has shown that some patients with atopic eczema have specific self-reactive antibodies, known as IgE autoantibodies, that react to their own skin cells, referred to as \"self-reactive antibodies\" or \"autoantibodies\". It is not yet known when and how these self-reactive antibodies develop, so this is what we aim to investigate.\n\nThis study aims to examine the presence of self-reactive antibodies at birth. In other words, the investigators want to study the earliest stage of developing antibodies that target the body's own skin cells. Additionally, factors that contribute to the development of these self-reactive antibodies will be explored as well as the correlation with the development of atopic eczema.\n\nThe study will involve newborns who are at an increased risk of developing atopic eczema due to a family history of asthma, hay fever, or atopic eczema. There will also be a control group of newborns without these characteristics. The study's approach is to examine a portion of the umbilical cord blood, which is routinely collected after birth, to investigate self-reactive antibodies. The goal is to determine whether these self-reactive antibodies are linked to the development of atopic eczema in the first two years of life. For this purpose, follow-ups will be conducted at the ages of 6, 12, and 24 months.\n\nThis study will contribute to an increased understanding of the prevalence of self-reactive antibodies and the factors influencing their development. Moreover, the study will determine whether these antibodies play a role in the prevention of and\u002For serve as predictive factors for the development of atopic eczema.",[612,613,614,615,616,617,618],"Atopic Dermatitis (AD)","Autoantibody","Auto-Immunity","Microbiome, Human","Allergic Disease","IgE-Mediated Hypersensitivity","Newborn Infant",[620,621,622,623,603],"Birth cohort","Autoantibodies","IgE","Atopic dermatitis","2025-12-18",{"date":626,"type":33},"2026-01-05",{"date":628,"type":33},"2023-10-01",{"date":630,"type":21},"2030-12-31",{"name":39,"class":40},{"id":633,"slug":634,"hasResults":12,"nctId":635,"briefTitle":636,"officialTitle":637,"acronym":638,"eligibilityCriteria":639,"healthyVolunteers":74,"sex":75,"minAge":18,"maxAge":640,"enrollmentInfo":641,"targetDuration":4,"studyType":22,"phases":643,"briefSummary":644,"conditions":645,"keywords":647,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":656,"completionDateStruct":658,"leadSponsor":660,"locationsCount":94},"100607390","evaluation-of-a-fully-automated-ai-tool-for-embryo-ranking-100607390","NCT07187934","EVALUATION OF A FULLY AUTOMATED AI TOOL FOR EMBRYO RANKING","PROSPECTIVE EVALUATION OF THE IDASCORE ALGORITHM FOR EMBRYO RANKING","PRIDE","Inclusion Criteria:\n\n* patients undergoing an ICSI\u002FIVF treatment (with donor or own oocytes) that are planned for a 'freeze-all' strategy on day 5\n* all types of sperm samples (ejaculated or testicular, fresh or frozen, partner or donor origin)\n* Minimum 8 follicles (≥ 12 mm) on last follicular measurement before oocyte retrieval\n* 18 ≤ Age ≤ 42 years\n* 18 ≤ BMI ≤ 35 kg\u002Fm²\n* Maximum third IVF\u002FICSI cycle\n* Participants can be included only once in the trial\n\nExclusion Criteria:\n\n* Embassy patients\n* Use of frozen oocytes\n* In vitro maturation (IVM) cycles\n* Pre-implantation genetic Testing (PGT) cycles\n* Proven untreated intra-uterine pathologies (e.g. Asherman syndrome, adenomysosis)\n* Endometriosis stage 3\u002F4","42 Years",{"count":642,"type":21},1325,[24],"This study aims to investigate whether embryo ranking by a fully automated AI tool (iDAScore) results in a similar transfer-to-pregnancy compared to manual embryo ranking by an embryologist. IVF patients who are planned for a freeze-all approach (where all usable embryos are frozen and transferred in later transfer cycles) will be allocated to either the control (ranking by embryologist) or intervention arm (ranking by iDAScore). The frozen embryos will be warmed and transferred one by one, according to their assigned rank. We want to see if the average number of embryo transfers that is needed to achieve a clinical pregnancy (transfer-to-pregnancy) is similar in both groups.",[646],"Pregnancy",[648,649,650,651,652],"iDA","AI","embryo ranking","transfer-to-pregnancy","time-lapse","2025-12-16",{"date":655,"type":33},"2025-12-23",{"date":657,"type":33},"2025-12-11",{"date":659,"type":21},"2029-10-01",{"name":39,"class":40},""]